<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38020172</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Editorial: Immune-mediated lung injury.</ArticleTitle><Pagination><StartPage>1292074</StartPage><MedlinePgn>1292074</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1292074</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2023.1292074</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karampitsakos</LastName><ForeName>Theodoros</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care and Sleep Medicine, Ubben Center for Pulmonary Fibrosis Research, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spagnolo</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzouvelekis</LastName><ForeName>Argyris</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Editorial on the Research Topic Immune-mediated lung injury</RefSource></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">idiopathic pulmonary fibrosis</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">monocytes</Keyword><Keyword MajorTopicYN="N">post-COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19-interstitial lung disease</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>14</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38020172</ArticleId><ArticleId IdType="pmc">PMC10655232</ArticleId><ArticleId IdType="doi">10.3389/fmed.2023.1292074</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kumar V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front Immunol. (2020) 11:1722. 10.3389/fimmu.2020.01722</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01722</ArticleId><ArticleId IdType="pmc">PMC7417316</ArticleId><ArticleId IdType="pubmed">32849610</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampitsakos T, Papaioannou O, Tsiri P, Katsaras M, Katsimpris A, Kalogeropoulos AP, et al. . Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clin Microbiol Infect. (2023) 29:372&#x2013;8. 10.1016/j.cmi.2022.10.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.10.015</ArticleId><ArticleId IdType="pmc">PMC9636985</ArticleId><ArticleId IdType="pubmed">36273769</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. (1976) 85:769&#x2013;88. 10.7326/0003-4819-85-6-769</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-85-6-769</ArticleId><ArticleId IdType="pubmed">793466</ArticleId></ArticleIdList></Reference><Reference><Citation>Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. The New England J Med. (2012) 366:1968&#x2013;77. 10.1056/NEJMoa1113354</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1113354</ArticleId><ArticleId IdType="pmc">PMC3422642</ArticleId><ArticleId IdType="pubmed">22607134</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, et al. . Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. Lancet Respir Med. (2019) 7:497&#x2013;508. 10.1016/S2213-2600(18)30508-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(18)30508-3</ArticleId><ArticleId IdType="pmc">PMC6529612</ArticleId><ArticleId IdType="pubmed">30935881</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampitsakos T, Torrisi S, Antoniou K, Manali E, Korbila I, Papaioannou O, et al. . Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with idiopathic pulmonary fibrosis. Respir Res. (2021) 22:140. 10.1186/s12931-021-01725-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01725-9</ArticleId><ArticleId IdType="pmc">PMC8097815</ArticleId><ArticleId IdType="pubmed">33952261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, et al. . Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. (2021) 204:74&#x2013;81. 10.1164/rccm.202003-0669OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0669OC</ArticleId><ArticleId IdType="pmc">PMC8437112</ArticleId><ArticleId IdType="pubmed">33434107</ArticleId></ArticleIdList></Reference><Reference><Citation>Herazo-Maya JD, Sun J, Molyneaux PL Li Q, Villalba JA, Tzouvelekis A, et al. . Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med. (2017) 5:857&#x2013;68. 10.1016/S2213-2600(17)30349-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(17)30349-1</ArticleId><ArticleId IdType="pmc">PMC5677538</ArticleId><ArticleId IdType="pubmed">28942086</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampitsakos T, Juan-Guardela BM, Tzouvelekis A, Herazo-Maya JD. Precision medicine advances in idiopathic pulmonary fibrosis. EBioMedicine. (2023) 95:104766. 10.1016/j.ebiom.2023.104766</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104766</ArticleId><ArticleId IdType="pmc">PMC10469771</ArticleId><ArticleId IdType="pubmed">37625268</ArticleId></ArticleIdList></Reference><Reference><Citation>Juan Guardela BM, Sun J, Zhang T, Xu B, Balnis J, Huang Y, et al. . 50-gene risk profiles in peripheral blood predict COVID-19 outcomes: a retrospective, multicenter cohort study. EBioMedicine. (2021) 69:103439. 10.1016/j.ebiom.2021.103439</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103439</ArticleId><ArticleId IdType="pmc">PMC8214725</ArticleId><ArticleId IdType="pubmed">34157486</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai SR, Hansell DM, Walker A, MacDonald SL, Chabat F, Wells AU. Quantification of emphysema: a composite physiologic index derived from CT estimation of disease extent. Eur Radiol. (2007) 17:911&#x2013;8. 10.1007/s00330-006-0369-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-006-0369-0</ArticleId><ArticleId IdType="pubmed">16941093</ArticleId></ArticleIdList></Reference><Reference><Citation>Melms JC, Biermann J, Huang H, Wang Y, Nair A, Tagore S, et al. . A molecular single-cell lung atlas of lethal COVID-19. Nature. (2021) 595:114&#x2013;9. 10.1038/s41586-021-03569-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03569-1</ArticleId><ArticleId IdType="pmc">PMC8814825</ArticleId><ArticleId IdType="pubmed">33915568</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J, Reusch N, Paclik D, Ba&#xdf;ler K, Schlickeiser S, Zhang B, et al. . Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. (2020) 182:1419&#x2013;40. 10.1016/j.cell.2020.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.001</ArticleId><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusnadi A, Ram&#xed;rez-Su&#xe1;stegui C, Fajardo V, Chee SJ, Meckiff BJ, Simon H, et al. . Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8(+) T cells. Sci Immunol. (2021) 6:782. 10.1126/sciimmunol.abe4782</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe4782</ArticleId><ArticleId IdType="pmc">PMC8101257</ArticleId><ArticleId IdType="pubmed">33478949</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023) 21:133&#x2013;46. 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Alahdal M, Elkord E. Exhaustion and over-activation of immune cells in COVID-19: challenges and therapeutic opportunities. Clin Immunol. (2022) 245:109177. 10.1016/j.clim.2022.109177</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109177</ArticleId><ArticleId IdType="pmc">PMC9640209</ArticleId><ArticleId IdType="pubmed">36356848</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Estrada BS, Denneny EK, Foster K, Turner CT, Mayer A, et al. . Single-cell analysis of bronchoalveolar cells in inflammatory and fibrotic post-COVID lung disease. medRxiv. (2023) 2023:23287759. 10.1101/2023.03.28.23287759</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.28.23287759</ArticleId><ArticleId IdType="pmc">PMC11140060</ArticleId><ArticleId IdType="pubmed">38827740</ArticleId></ArticleIdList></Reference><Reference><Citation>Tourki B, Vera I, Perrot C, Farsaei F, Arsenault A, Juan-Guardela B, et al. . Peripheral Blood Gene Expression Changes Predict Mortality and Treatment Response in Acute COVID-19 and Associate with Lung Fibrosis. In: c32 Interrogation of Genetic Variation, Gene Expression, and Other Biological Layers With Omics Techniques to Understand Respiratory Traits. Washington, DC: American Thoracic Society; (2022), p. A3929-A.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>